期刊
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
卷 135, 期 34, 页码 12707-12721出版社
AMER CHEMICAL SOC
DOI: 10.1021/ja4049493
关键词
-
资金
- Nordion (Canada)
- Natural Sciences and Engineering Research Council (NSERC) of Canada
- NSERC
- University of British Columbia
- Canada Council for the Arts
- University of Canterbury
- Alexander von Humboldt Foundation
- NIH [R24 CA83084, P30 CA08748, 1F32CA1440138-01]
- DOE [DE-SC0002184]
A bifunctional derivative of the versatile acyclic chelator H(4)octapa, p-SCN-Bn-H(4)octapa, has been synthesized for the first time. The chelator was conjugated to the HER2/neutargeting antibody trastuzumab and labeled in high radiochemical purity and specific activity with the radioisotopes In-111 and Lu-177. The in vivo behavior of the resulting radio-immunoconjugates was investigated in mice bearing ovarian cancer xenografts and compared to analogous radioimmuno-conjugates employing the ubiquitous chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). The H(4)octapa-trastuzumab conjugates displayed faster radiolabeling kinetics with more reproducible yields under milder conditions (15 min, RT, similar to 94-95%) than those based on DOTA-trastuzumab (60 min, 37 degrees C, similar to 50-88%). Further, antibody integrity was better preserved in the In-111- and Lu-177-octapa-trastuzumab constructs, with immunoreactive fractions of 0.99 for each compared to 0.93-0.95 for In-111- and Lu-177-DOTA-trastuzumab. These results translated to improved in vivo biodistribution profiles and SPECT imaging results for In-111- and Lu-177-octapa-trastuzumab compared to In-111- and Lu-177-DOTA-trastuzumab, with increased tumor uptake and higher tumor-to-tissue activity ratios.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据